Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | RARA | P10276 | 1/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.69 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.67 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | THRA | P10827 | 5/20 | 0.56 |
| ▸ | THRB | P10828 | 5/20 | 0.56 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188800 | 1.00 | RARB (0.69) | RARBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL2401275 | 1.00 | RARB (0.69) | RARBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL20874436 | 1.00 | RARB (0.69) | RARBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL19288566 | 0.98 | RARB (0.69) | RARBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL10986414 | 0.95 | CYP4A11 (0.73) | RARBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL14660877 | 0.95 | CYP4A11 (0.73) | RARBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL12814607 | 0.95 | CYP4A11 (0.73) | RARBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6069166 | 0.95 | CYP4A11 (0.73) | RARBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6024028 | 0.95 | CYP4A11 (0.73) | RARBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL4308585 | 0.95 | CYP4A11 (0.73) | RARBMAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388338-B2 | Liquid crystal mixture | MERCK PATENT GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-8377331-B2 | Liquid crystals composition and liquid crystal display with patterned electrodes | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377331-B2 | Liquid crystals composition and liquid crystal display with patterned electrodes | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110075074-A1 | Liquid Crystals Composition and Liquid Crystal Display with Patterned Electrodes | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110075074-A1 | Liquid Crystals Composition and Liquid Crystal Display with Patterned Electrodes | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1907347-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | Arcadia Pharmaceuticals Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20060011886-A1 | Liquid crystal mixture | LI JI | 2006-01-19 | — | — | US | disclosed |
| US-6958176-B2 | Liquid crystal mixture | AZ ELECTRONIC MATERIALS (GERMANY) GMBH (DE) | 2005-10-25 | — | — | US | disclosed |
| EP-1319054-B1 | LIQUID CRYSTAL MIXTURE | CLARIANT INT LTD (CH) | 2005-03-16 | — | — | EP | disclosed |
| US-20040085490-A1 | Liquid crystal mixture | AZ ELECTRONIC MATERIALS (GERMANY) GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | RARB, RARA, RARG | RARB 1/4885MAPT 810/4885MEN1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.